Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review

Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review

Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE), remain a focus of extensive research and clinical...

Full description

Bibliographic Details
Main Authors: Krasimir Kraev, Mariela Gencheva Geneva-Popova, Bozhidar Krasimirov Hristov, Petar Angelov Uchikov, Stanislava Dimitrova Belova-Popova, Maria Ilieva Kraeva, Yordanka Mincheva Basheva-Kraeva, Nina Staneva Stoyanova, Vesela Todorova Mitkova-Hristova, Maria Stoyanova Koleva-Ivanova, Daniela Ivova Taneva, Atanas Slavchev Ivanov
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Life
Subjects:
JAK inhibitors
immune-mediated diseases
safety profile
adverse events
Online Access:https://www.mdpi.com/2075-1729/13/12/2244

Internet

https://www.mdpi.com/2075-1729/13/12/2244

Similar Items